🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Melvin LK CHUA | FRCR, PhD, FASCO Nadeem Riaz Ravi Uppaluri, MDPhD And the TPS score data?

Thanks John B. Sunwoo, M.D. !!! Great day for our patients!

Keytruda Plus SOC: New Standard for Advanced Head & Neck Cancer | #AACR25 Ravi Uppaluri, MDPhD Dana-Farber hubs.li/Q03k6bMg0

#KEYNOTE689: Adding #Pembrolizumab before and after surgery significantly improves EFS in resectable LA-HNSCC. A potential new standard of care after 20+ years of stagnation. bit.ly/4cVzF0j #LARVOL #AACR25 #HNSCC #CancerResearch Ravi Uppaluri, MDPhD

Adding perioperative pembrolizumab to standard of care is “a new frontier” for head and neck cancer, Dana-Farber's Ravi Uppaluri, MDPhD tells Healio. Read more: bit.ly/435ercJ

As #HeadAndNeckCancer Month comes to a close, we reflect on the exciting phase 3 clinical trial results shared by Dana-Farber's Ravi Uppaluri, MDPhD in AJMC showing significantly extended event-free survival for patients with locally advanced head and neck cancer. Robert Haddad

“It’s really exciting. It’s a new frontier for our patients.” Ravi Uppaluri, MDPhD of Dana-Farber discussed data from KEYNOTE-689 trial that showed KEYTRUDA (pembrolizumab) significantly extended EFS for patients with advanced HNSCC. AACR Brigham and Women's Hospital Harvard Medical School bit.ly/3YPEsdE

If you are attending AHNS, please join Dr. Stephen Lai & me this evening (Wed) in Celestin E at 6:15pm for updates on NRG Oncology HN006 AND to hear PRACTICE CHANGING data from Keynote 689, the Ph3 trial of perioperative pembrolizumab recently presented AACR by Ravi Uppaluri, MDPhD

Boom!💥 ⁦FDA⁩ approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma, ushering in a new standard of care for the first time in decades. fda.gov/drugs/resource…

The standard of care has finally changed for patients with resectable head and neck #cancer!! Congratulations Ravi Uppaluri, MDPhD and all the #KN-689 investigators. fda.gov/drugs/resource…

merck.com/news/fda-appro…

Thanks Gopal Iyer !!! Has been quite a journey from an idea we had in the early 2010s to change standard of care (with DAdkins at WashU as a partner on all this work)- exciting news for our patients.

#BREAKING The FDA has approved pembrolizumab as the first new standard-of-care treatment for patients with resectable locally advanced #HeadandNeck cancer in 20+ years. Approval based on the pivotal KEYNOTE-689 trial led by Ravi Uppaluri, MDPhD of the Dana-Farber Brigham Cancer Center.

The results of the KEYNOTE-689 trial that served as the basis for this approval were recently presented by Ravi Uppaluri, MDPhD of @HarvardMed and Brigham and Women's Hospital at #AACR25. Read more about the trial results on the #AACRBlog: aacr.org/blog/2025/04/3…

Exciting news in the head and neck cancer space. KEYNOTE-689 resulted in the first FDA approval for patients with HNSCC in 6 years. Congrats to Ravi Uppaluri, MDPhD, Doug Adkins, and the rest of the team worldwide. fda.gov/drugs/resource…

FDA approves pembrolizumab for resectable, locally advanced HNSCC based on KEYNOTE‑689. Led by Dr. Ravindra Uppaluri Ravi Uppaluri, MDPhD, the study showed a 30% drop in recurrence risk. Full details from The ASCO Post: ascopost.com/news/june-2025… #HNSCC #Oncology